CCR1

C-C chemokine receptor type 1 · P32246 · CCR1 on Sugi Atlas →

120,687 patent compounds predicted against CCR1, 59,753 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL303982	0.48	9/20
Difenoximide (SCHEMBL121671)	0.51	8/20
SCHEMBL247884	0.51	7/20
SCHEMBL307176	0.45	7/20
SCHEMBL28973	0.45	7/20
SCHEMBL46486	0.38	7/20
SCHEMBL46781	0.38	7/20
Phenanthroline (SCHEMBL226209)	0.73	6/20
Difenoxin (SCHEMBL123801)	0.61	6/20
Difenoxin (SCHEMBL149008)	0.60	6/20
SCHEMBL250356	0.57	6/20
SCHEMBL46481	0.40	6/20
Phenanthroline (SCHEMBL8312)	1.00	5/20
SCHEMBL136654	1.00	5/20
SCHEMBL182930	1.00	5/20
Phenanthroline (SCHEMBL44857)	0.94	5/20
1-Naphthoquinoline (SCHEMBL15106)	0.68	5/20
1-Naphthoquinoline (SCHEMBL262791)	0.65	5/20
SCHEMBL67041	0.64	5/20
SCHEMBL67915	0.64	5/20

Clinical trials — most relevant to CCR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia	PHASE3	SUSPENDED
Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation	PHASE3	SUSPENDED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Polyvalent Immunoglobulin in COVID-19 Related ARds	PHASE3	COMPLETED
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients	PHASE1/PHASE2	COMPLETED
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment	PHASE2	UNKNOWN
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver	PHASE2	COMPLETED
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)	PHASE1	RECRUITING
Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation	PHASE1	COMPLETED
U69-CART-Cells For R/R T-ALL	PHASE1	RECRUITING
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation	PHASE1	RECRUITING
GSK2239633 FTIH Study	PHASE1	COMPLETED
NIH CCR2 AAA Study	EARLY_PHASE1	COMPLETED
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response	nan	ACTIVE_NOT_RECRUITING
Evaluation of CCR6 Gene Expression and Circulating CCL20 Levels as Potential Biomarkers in Rheumatoid Arthritis	nan	NOT_YET_RECRUITING
IL-11 in the Development of Multiple Sclerosis	nan	UNKNOWN
Monocyte Chemoattractant Protein-1 in Psoriatic Arthritis Patients	nan	UNKNOWN
Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)	nan	COMPLETED
Circular RNA and Chemerin in Breast Cancer Patient	nan	UNKNOWN
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma	nan	UNKNOWN
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy	nan	COMPLETED
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma	nan	UNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure	nan	UNKNOWN
Lung-Resident Memory Th2 Cells in Asthma	nan	ACTIVE_NOT_RECRUITING
Inflammatory Biomarkers in Seizure	nan	UNKNOWN
Measuring the Healthy Pediatric Inflammatory Response to Vaccination.	nan	ENROLLING_BY_INVITATION
Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720)	nan	UNKNOWN
Evaluation of Macrophage Inflammatory Protein-1α as a Periodontal Disease Biomarker	nan	COMPLETED
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CCR1 binder may also engage these)

Protein	Name	Similarity
Q2Y2P0	—	1.000	Q2Y2P0 →
O54814	—	1.000	O54814 →
P56482	—	1.000	P56482 →
Q9BDS8	—	1.000	Q9BDS8 →
P56493	—	1.000	P56493 →
Q64H34	—	1.000	Q64H34 →
Q9TSQ8	—	1.000	Q9TSQ8 →
Q95ND1	—	1.000	Q95ND1 →
Q9N0Z0	—	1.000	Q9N0Z0 →
Q95NC1	—	1.000	Q95NC1 →
P56492	—	1.000	P56492 →
P35411	—	1.000	P35411 →
Q9Z2I3	—	1.000	Q9Z2I3 →
Q95NC6	—	1.000	Q95NC6 →
O97882	—	1.000	O97882 →
Q9TV47	—	1.000	Q9TV47 →
O62743	—	0.999	O62743 →
P61814	—	0.999	P61814 →
P61813	—	0.999	P61813 →
Q6WN98	—	0.999	Q6WN98 →
Q95NC9	—	0.999	Q95NC9 →
Q95ND2	—	0.999	Q95ND2 →
Q95NC2	—	0.999	Q95NC2 →
Q9TV42	—	0.999	Q9TV42 →
Q95NC8	—	0.999	Q95NC8 →
P51675	—	0.999	P51675 →
P61815	—	0.999	P61815 →
Q9BGN6	—	0.999	Q9BGN6 →
Q95ND0	—	0.999	Q95ND0 →
O97878	—	0.999	O97878 →